Ixico reports progress in Huntington's disease imaging consortium

The AIM-traded firm said that in June, an additional bio-pharma partner joined the consortium, which originally included the CHDI Foundation, uniQure, PTC Therapeutics, and Asklepios BioPharmaceutical.

Using Ixico’s AI-powered IXIQ.Ai platform, the consortium had analysed more than 6,000 MRI scans, generating data that supports using imaging biomarkers as clinical trial endpoints.

Preliminary findings presented by Dr Marina Papoutsi at the February HD-TC conference demonstrated the potential of brain volume changes as surrogate trial endpoints.

HD-IH was continuing to seek new partners to expand its biomarker development programme, aiming to enhance the precision and efficacy of clinical trials for Huntington's disease.

“We are delighted with the progress made in the HD-IH consortium over the past year,” said chief scientific officer Dr Robin Wolz.

“The results presented at the HD-TC conference show how the initial data generated via this partnership provides additional evidence of the impact that MRI-based biomarkers have in HD clinical development.”

Dr Wolz said the further expansion in the number of HD-IH biopharmaceutical partners demonstrated the value the collaboration provided to the industry.

“By completing the analysis of the available data over the remainder of 2024 and focusing on the resulting biomarker evidence, the consortium will provide unique scientific understanding and insights for successful operational implementation of those measurements in clinical development.”

Reporting by Josh White for Sharecast.com.